메뉴 건너뛰기




Volumn 20, Issue 13, 2014, Pages 2205-2211

Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis

Author keywords

Cannabis; Meta analysis; Schizophrenia

Indexed keywords

ARTICLE; CANNABIS USE; COGNITIVE THERAPY; COMORBIDITY; HUMAN; META ANALYSIS; MOTIVATIONAL INTERVIEWING; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CLINICAL TRIAL (TOPIC); MARIJUANA ABUSE; MOTIVATION; PSYCHOTIC DISORDERS;

EID: 84903743576     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990431     Document Type: Article
Times cited : (17)

References (44)
  • 1
    • 26644453329 scopus 로고    scopus 로고
    • Cannabis use and misuse prevalence among people with psychosis
    • Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187: 306-13.
    • (2005) Br J Psychiatry , vol.187 , pp. 306-313
    • Green, B.1    Young, R.2    Kavanagh, D.3
  • 3
    • 0036789677 scopus 로고    scopus 로고
    • Medication adherence of individuals with a first episode of psychosis
    • Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-90.
    • (2002) Acta Psychiatr Scand , vol.106 , pp. 286-290
    • Coldham, E.L.1    Addington, J.2    Addington, D.3
  • 4
    • 0030698640 scopus 로고    scopus 로고
    • Determinants of medication compliance in schizophrenia: Empirical and clinical findings
    • Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-51.
    • (1997) Schizophr Bull , vol.23 , pp. 637-651
    • Fenton, W.S.1    Blyler, C.R.2    Heinssen, R.K.3
  • 6
    • 33747170367 scopus 로고    scopus 로고
    • Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study
    • Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 2006; 189: 137-43.
    • (2006) Br J Psychiatry , vol.189 , pp. 137-143
    • Hides, L.1    Dawe, S.2    Kavanagh, D.J.3    Young, R.M.4
  • 7
    • 0028316414 scopus 로고
    • Cannabis abuse and the course of recent-onset schizophrenic disorders
    • Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9.
    • (1994) Arch Gen Psychiatry , vol.51 , pp. 273-279
    • Linszen, D.H.1    Dingemans, P.M.2    Lenior, M.E.3
  • 8
    • 68049139264 scopus 로고    scopus 로고
    • A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia
    • Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 2009; 113: 138-44.
    • (2009) Schizophr Res , vol.113 , pp. 138-144
    • Miller, R.1    Ream, G.2    McCormack, J.3    Gunduz-Bruce, H.4    Sevy, S.5    Robinson, D.6
  • 9
    • 0033950999 scopus 로고    scopus 로고
    • Predicting Medication Noncompliance After Hospital Discharge Among Patients With Schizophrenia
    • Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting Medication Noncompliance After Hospital Discharge Among Patients With Schizophrenia. Psychiatr Serv 2000; 51: 216-22.
    • (2000) Psychiatr Serv , vol.51 , pp. 216-222
    • Olfson, M.1    Mechanic, D.2    Hansell, S.3    Boyer, C.A.4    Walkup, J.5    Weiden, P.J.6
  • 10
    • 78049434577 scopus 로고    scopus 로고
    • Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis
    • van Nimwegen-Campailla L, van Beveren N, Laan W, van den Brink W, Linszen D, de Haan L. Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis. Pharmacopsychiatry 2010; 43: 81.
    • (2010) Pharmacopsychiatry , vol.43 , pp. 81
    • van Nimwegen-Campailla, L.1    van Beveren, N.2    Laan, W.3    van den Brink, W.4    Linszen, D.5    de Haan, L.6
  • 12
    • 38049059152 scopus 로고    scopus 로고
    • Alcohol and cannabis use in Urban, African American, first-episode schizophreniaspectrum patients: Associations with positive and negative symptoms
    • Compton MT, Whicker NE, Hochman KM. Alcohol and cannabis use in Urban, African American, first-episode schizophreniaspectrum patients: associations with positive and negative symptoms. J Clin Psychiatry 2007; 68: 1939-45.
    • (2007) J Clin Psychiatry , vol.68 , pp. 1939-1945
    • Compton, M.T.1    Whicker, N.E.2    Hochman, K.M.3
  • 13
    • 84857572453 scopus 로고    scopus 로고
    • The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Metaanalysis of Existing Findings and New Data in a First-Episode Sample
    • Yücel M, Bora E, Lubman DI, et al. The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Metaanalysis of Existing Findings and New Data in a First-Episode Sample. Schizophr Bull 2012; 38: 316-30.
    • (2012) Schizophr Bull , vol.38 , pp. 316-330
    • Yücel, M.1    Bora, E.2    Lubman, D.I.3
  • 14
    • 15744398700 scopus 로고    scopus 로고
    • Delta-9- tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
    • D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9- tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608.
    • (2005) Biol Psychiatry , vol.57 , pp. 594-608
    • D'Souza, D.C.1    Abi-Saab, W.M.2    Madonick, S.3
  • 15
    • 3242789385 scopus 로고    scopus 로고
    • The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
    • D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-72.
    • (2004) Neuropsychopharmacology , vol.29 , pp. 1558-1572
    • D'Souza, D.C.1    Perry, E.2    Macdougall, L.3
  • 16
    • 70449629796 scopus 로고    scopus 로고
    • The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning
    • Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009; 39: 1607-16.
    • (2009) Psychol Med , vol.39 , pp. 1607-1616
    • Morrison, P.D.1    Zois, V.2    McKeown, D.A.3
  • 17
    • 64849106877 scopus 로고    scopus 로고
    • Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: A neural basis for the effects of Cannabis sativa on learning and psychosis
    • Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009; 66: 442-51.
    • (2009) Arch Gen Psychiatry , vol.66 , pp. 442-451
    • Bhattacharyya, S.1    Fusar-Poli, P.2    Borgwardt, S.3
  • 18
    • 58149520644 scopus 로고    scopus 로고
    • Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing
    • Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66: 95-105.
    • (2009) Arch Gen Psychiatry , vol.66 , pp. 95-105
    • Fusar-Poli, P.1    Crippa, J.A.2    Bhattacharyya, S.3
  • 19
    • 77950337098 scopus 로고    scopus 로고
    • Treatment of cannabis use among people with psychotic or depressive disorders: A systematic review
    • Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. J Clin Psychiatry 2010; 71: 247-54.
    • (2010) J Clin Psychiatry , vol.71 , pp. 247-254
    • Baker, A.L.1    Hides, L.2    Lubman, D.I.3
  • 21
    • 67349084022 scopus 로고    scopus 로고
    • Treatment of cannabis use disorders in people with schizophrenia spectrum disorders -- A systematic review
    • Hjorthøj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders -- A systematic review. Addict Behav 2009; 34: 520-5.
    • (2009) Addict Behav , vol.34 , pp. 520-525
    • Hjorthøj, C.1    Fohlmann, A.2    Nordentoft, M.3
  • 22
    • 46449124620 scopus 로고    scopus 로고
    • Handling drop-out in longitudinal clinical trials: A comparison of the LOCF and MMRM approaches
    • Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008; 7: 93-106.
    • (2008) Pharm Stat , vol.7 , pp. 93-106
    • Lane, P.1
  • 23
    • 50449104090 scopus 로고    scopus 로고
    • Comparison of data analysis strategies for intent-to-treat analysis in pre-test-posttest designs with substantial dropout rates
    • Salim A, Mackinnon A, Christensen H, Griffiths K. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-posttest designs with substantial dropout rates. Psychiatry Res 2008; 160: 335-45.
    • (2008) Psychiatry Res , vol.160 , pp. 335-345
    • Salim, A.1    Mackinnon, A.2    Christensen, H.3    Griffiths, K.4
  • 24
    • 2942695870 scopus 로고    scopus 로고
    • Controlling the risk of spurious findings from meta-regression
    • Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-82.
    • (2004) Stat Med , vol.23 , pp. 1663-1682
    • Higgins, J.P.1    Thompson, S.G.2
  • 27
    • 84903712233 scopus 로고    scopus 로고
    • Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: The CapOpus randomized trial
    • Hjorthøj CR, Fohlmann A, Larsen AM, Gluud C, Arendt M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. Psychol Med 2012; 1-12.
    • (2012) Psychol Med , pp. 1-12
    • Hjorthøj, C.R.1    Fohlmann, A.2    Larsen, A.M.3    Gluud, C.4    Arendt, M.5    Nordentoft, M.6
  • 28
    • 84903721161 scopus 로고    scopus 로고
    • A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness
    • Madigan K, Brennan D, Lawlor E, et al. A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res.
    • Schizophr Res
    • Madigan, K.1    Brennan, D.2    Lawlor, E.3
  • 29
    • 84863968104 scopus 로고    scopus 로고
    • Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: A randomized controlled trial
    • Smeerdijk M, Keet R, Dekker N, et al. Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial. Psychol Med 2012; 42: 1627-36.
    • (2012) Psychol Med , vol.42 , pp. 1627-1636
    • Smeerdijk, M.1    Keet, R.2    Dekker, N.3
  • 30
    • 33646528220 scopus 로고    scopus 로고
    • Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial
    • Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. Br J Psychiatry 2006; 188: 439-48.
    • (2006) Br J Psychiatry , vol.188 , pp. 439-448
    • Baker, A.1    Bucci, S.2    Lewin, T.J.3    Kay-Lambkin, F.4    Constable, P.M.5    Carr, V.J.6
  • 31
    • 85047682462 scopus 로고    scopus 로고
    • Integrated care for cooccurring disorders: Psychiatric symptoms, social functioning, and service costs at 18 months
    • Craig TK, Johnson S, McCrone P, et al. Integrated care for cooccurring disorders: psychiatric symptoms, social functioning, and service costs at 18 months. Psychiatr Serv 2008; 59: 276-82.
    • (2008) Psychiatr Serv , vol.59 , pp. 276-282
    • Craig, T.K.1    Johnson, S.2    McCrone, P.3
  • 32
    • 33745818603 scopus 로고    scopus 로고
    • Randomized controlled trial of a cannabis-focused intervention for young people with firstepisode psychosis
    • Edwards J, Elkins K, Hinton M, et al. Randomized controlled trial of a cannabis-focused intervention for young people with firstepisode psychosis. Acta Psychiatr Scand 2006; 114: 109-17.
    • (2006) Acta Psychiatr Scand , vol.114 , pp. 109-117
    • Edwards, J.1    Elkins, K.2    Hinton, M.3
  • 33
    • 33748342123 scopus 로고    scopus 로고
    • A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders
    • Martino S, Carroll KM, Nich C, Rounsaville BJ. A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 2006; 101: 1479-92.
    • (2006) Addiction , vol.101 , pp. 1479-1492
    • Martino, S.1    Carroll, K.M.2    Nich, C.3    Rounsaville, B.J.4
  • 34
    • 0031974871 scopus 로고    scopus 로고
    • Outcomes of Homeless Mentally Ill Chemical Abusers in Community Residences and a Therapeutic Community
    • Nuttbrock LA, Rahav M, Rivera JJ, Ng-Mak DS, Link BG. Outcomes of Homeless Mentally Ill Chemical Abusers in Community Residences and a Therapeutic Community. Psychiatr Serv 1998; 49: 68-76.
    • (1998) Psychiatr Serv , vol.49 , pp. 68-76
    • Nuttbrock, L.A.1    Rahav, M.2    Rivera, J.J.3    Ng-Mak, D.S.4    Link, B.G.5
  • 35
    • 84903712233 scopus 로고    scopus 로고
    • Specialized psychosocial treatment plus treatment as usual versus treatment as usual for patients with cannabis use disorder and psychosis - the CapOpus randomised trial
    • In press
    • Hjorthøj CR, Fohlmann A, Larsen AM, Gluud C, Arendt MC, Nordentoft M. Specialized psychosocial treatment plus treatment as usual versus treatment as usual for patients with cannabis use disorder and psychosis - the CapOpus randomised trial. Psychol Med 2012; In press.
    • (2012) Psychol Med
    • Hjorthøj, C.R.1    Fohlmann, A.2    Larsen, A.M.3    Gluud, C.4    Arendt, M.C.5    Nordentoft, M.6
  • 36
    • 79960774988 scopus 로고    scopus 로고
    • Motivational intervention to reduce cannabis use in young people with psychosis: A randomized controlled trial
    • Bonsack C, Gibellini MS, Favrod J, et al. Motivational intervention to reduce cannabis use in young people with psychosis: a randomized controlled trial. Psychother Psychosom 2011; 80: 287-97.
    • (2011) Psychother Psychosom , vol.80 , pp. 287-297
    • Bonsack, C.1    Gibellini, M.S.2    Favrod, J.3
  • 37
    • 0026474144 scopus 로고
    • Stages of change in the modification of problem behaviors
    • Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Prog Behav Modif 1992; 28: 183-218.
    • (1992) Prog Behav Modif , vol.28 , pp. 183-218
    • Prochaska, J.O.1    Diclemente, C.C.2
  • 38
    • 60349086480 scopus 로고    scopus 로고
    • A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
    • Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-63.
    • (2009) Am J Psychiatry , vol.166 , pp. 152-163
    • Leucht, S.1    Komossa, K.2    Rummel-Kluge, C.3
  • 39
    • 33746125842 scopus 로고    scopus 로고
    • Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial
    • Potvin S, Stip E, Lipp O, Elie R, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006; 22: 1277-85.
    • (2006) Curr Med Res Opin , vol.22 , pp. 1277-1285
    • Potvin, S.1    Stip, E.2    Lipp, O.3    Elie, R.4
  • 40
    • 84858391237 scopus 로고    scopus 로고
    • Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
    • Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94.
    • (2012) Transl Psychiatry , vol.2
    • Leweke, F.M.1    Piomelli, D.2    Pahlisch, F.3
  • 41
    • 77954761129 scopus 로고    scopus 로고
    • Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis
    • Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010; 35: 1879-85.
    • (2010) Neuropsychopharmacology , vol.35 , pp. 1879-1885
    • Morgan, C.J.1    Freeman, T.P.2    Schafer, G.L.3    Curran, H.V.4
  • 42
    • 84855316451 scopus 로고    scopus 로고
    • Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing
    • Bhattacharyya S, Crippa JA, Allen P, et al. Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012; 69: 27-36.
    • (2012) Arch Gen Psychiatry , vol.69 , pp. 27-36
    • Bhattacharyya, S.1    Crippa, J.A.2    Allen, P.3
  • 43
    • 75749126485 scopus 로고    scopus 로고
    • Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology
    • Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-74.
    • (2010) Neuropsychopharmacology , vol.35 , pp. 764-774
    • Bhattacharyya, S.1    Morrison, P.D.2    Fusar-Poli, P.3
  • 44
    • 0037098178 scopus 로고    scopus 로고
    • How should meta-regression analyses be undertaken and interpreted?
    • Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-73.
    • (2002) Stat Med , vol.21 , pp. 1559-1573
    • Thompson, S.G.1    Higgins, J.P.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.